Vistagen reports fiscal 2024 third quarter financial results and provides corporate update

South san francisco, calif.--(business wire)---- $vtgn #mentalhealth--vistagen (nasdaq: vtgn), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today reported financial results for its fiscal year 2024 third quarter ended december 31, 2023 and provided a corporate update. "momentum from clinical and corporate milestones achieved through the end of last quarter have significantly advanced our efforts to develop and co.
VTGN Ratings Summary
VTGN Quant Ranking